The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Open accessAbstract
Objective: Epilepsy is a major manifestation of tuberous sclerosis complex (TSC). Everolimus is an mammalian target of rapamycin complex 1 inhibitor with demonstrated benefit in several aspects of TSC. We report the first prospective human clinical trial to directly assess whether everolimus will also benefit epilepsy in TSC patients. Methods: The effect of everolimus on seizure control was assessed using a prospective, multicenter, open‐label, phase I/II clinical trial. Patients ≥2 years of age with confirmed diagnosis of TSC and medically refractory epilepsy were treated for a total of 12 weeks. The primary endpoint was percentage of patients with a ≥50% reduction in seizure frequency over a 4‐week period before and after treatment. Secondary endpoints assessed impact on electroencephalography (EEG), behavior, and quality of life. Results: Twenty‐three patients were enrolled, and 20 patients were treated with everolimus. Seizure frequency was reduced by ≥50% in 12 of 20 subjects. Overall, seizures were reduced in 17 of the 20 by a median reduction of 73% ( p < 0.001). Seizure frequency was also reduced during 23‐hour EEG monitoring ( p = 0.007). Significant reductions in seizure duration and improvement in parent‐reported behavior and quality of life were also observed. There were 83 reported adverse events that were thought to be treatment‐related, all of which were mild or moderate in severity. Interpretation: Seizure control improved in the majority of TSC patients with medically refractory epilepsy following treatment with everolimus. Everolimus demonstrated additional benefits on behavior and quality of life. Treatment was safe and well tolerated. Everolimus may be a therapeutic option for refractory epilepsy in this population. Ann Neurol 2013;74:679–687
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · cited 1×
“TSC1 and TSC2 form a complex responsible for the regulation of the mammalian target of rapamycin complex 1 (mTORC1) via the intermediary signaling protein Rheb (ras homolog enriched in brain).(7) Pharmacologic inhibitors of mTORC1, particularly sirolimus and everolimus, have demonstrated efficacy for the treatment of…”
BackgroundEfficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882
Meikle, L., Talos, D. M., Onda, H., Pollizzi, K., Rotenberg, A., Sahin, M., Jensen, F. E., & Kwiatkowski, D. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5540-06.2007 · Cited by 462
Wong, M. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02341.x · Cited by 205
Validation of the Quality of Life in Childhood Epilepsy Questionnaire in American epilepsy patients
Sabaz, M., Lawson, J. A., Cairns, D. R., Duchowny, M. S., Resnick, T. J., Dean, P. M., & Bye, A. M. E. (2003) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.08.012 · Cited by 136
Sha, L.-Z., Xing, X.-L., Zhang, D., Yao, Y., Dou, W.-C., Jin, L.-R., Wu, L.-W., & Xu, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039152 · Cited by 70
Cited by
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31419-2 · Cited by 764
Self-citationNeurological and neuropsychiatric aspects of tuberous sclerosis complex
Curatolo, P., Moavero, R., & de Vries, P. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00069-1 · Cited by 600
mTOR complexes in neurodevelopmental and neuropsychiatric disorders
Costa-Mattioli, M., & Monteggia, L. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3546 · Cited by 367
Jansen, L. A., Mirzaa, G. M., Ishak, G. E., O'Roak, B. J., Hiatt, J. B., Roden, W. H., Gunter, S. A., Christian, S. L., Collins, S., Adams, C., et al. (2015) · Brain · doi:10.1093/brain/awv045 · Cited by 364
The mTOR signalling cascade: paving new roads to cure neurological disease
Crino, P. B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.81 · Cited by 368
Metadata
- Authors
- Krueger, D. A., Wilfong, A. A., Holland‐Bouley, K., Anderson, A. E., Agricola, K., Tudor, C., Mays, M., Lopez, C. M., Kim, M., & Franz, D. N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2013-09-10
- Volume
- 74
- Issue
- 5
- Pages
- 679-687
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1574898460
- Cited by
- 389
- References
- 8
- FWCI
- 30.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. https://app.cochat.ai/papers/10.1002/ana.23960
- The paper
- Krueger, D. A., Wilfong, A. A., Holland‐Bouley, K., Anderson, A. E., Agricola, K., Tudor, C., Mays, M., Lopez, C. M., Kim, M., & Franz, D. N. (2013). Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Annals of Neurology. https://doi.org/10.1002/ana.23960
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.